Man Group PLC Esperion Therapeutics, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 25,692 shares of ESPR stock, worth $53,953. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,692

Holding current value

$53,953

% of portfolio

0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.61 - $2.73 $41,364 - $70,139	25,692 New	25,692 $42,000
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $452,045 - $675,830	223,785 Added 103.13%	440,770 $1.18 Million
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $122,319 - $516,087	167,561 Added 339.03%	216,985 $648,000
Q3 2023 Nov 14, 2023	SELL	$0.96 - $1.79 $65,113 - $121,410	-67,827 Reduced 57.85%	49,424 $48,000
Q2 2023 Aug 14, 2023	BUY	$1.2 - $1.76 $54,730 - $80,271	45,609 Added 63.66%	117,251 $162,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $78,171 - $390,856	53,542 Added 295.81%	71,642 $113,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $92,129 - $153,850	18,100 New	18,100 $112,000
Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $313,389 - $438,219	-65,700 Reduced 58.19%	47,203 $300,000
Q1 2022 May 16, 2022	BUY	$3.34 - $5.56 $377,096 - $627,740	112,903 New	112,903 $524,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $75,786 - $187,811	-15,756 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $22,430 - $42,269	1,978 Added 14.36%	15,756 $190,000
Q2 2021 Aug 16, 2021	SELL	$19.4 - $28.71 $276,411 - $409,060	-14,248 Reduced 50.84%	13,778 $291,000
Q1 2021 May 17, 2021	SELL	$25.12 - $36.89 $239,996 - $352,447	-9,554 Reduced 25.42%	28,026 $786,000
Q4 2020 Feb 16, 2021	BUY	$24.2 - $35.76 $483,249 - $714,091	19,969 Added 113.39%	37,580 $977,000
Q3 2020 Nov 16, 2020	BUY	$31.18 - $52.71 $8,761 - $14,811	281 Added 1.62%	17,611 $655,000
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $330,199 - $563,999	10,992 Added 173.43%	17,330 $889,000
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $7.59 Million - $20.4 Million	-276,658 Reduced 97.76%	6,338 $200,000
Q4 2019 Feb 18, 2020	BUY	$35.4 - $59.82 $2.7 Million - $4.57 Million	76,369 Added 36.96%	282,996 $16.9 Million
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $1.79 Million - $2.47 Million	-52,056 Reduced 20.12%	206,627 $7.58 Million
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $985,096 - $1.29 Million	24,566 Added 10.49%	258,683 $12 Million
Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $2.82 Million - $3.77 Million	70,331 Added 42.94%	234,117 $9.4 Million
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $747,863 - $1.2 Million	20,218 Added 14.08%	163,786 $7.54 Million
Q3 2018 Nov 14, 2018	BUY	$40.74 - $51.41 $4.9 Million - $6.19 Million	120,357 Added 518.53%	143,568 $6.37 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $840,238 - $1.77 Million	23,211 New	23,211 $910,000

Others Institutions Holding ESPR

# of Institutions

206

Shares Held

128M

Call Options Held

1.63M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $140M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account